<?xml version='1.0' encoding='utf-8'?>
<document id="31564513"><sentence text="Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects."><entity charOffset="34-45" id="DDI-PubMed.31564513.s1.e0" text="Telmisartan" /><entity charOffset="47-57" id="DDI-PubMed.31564513.s1.e1" text="Amlodipine" /><entity charOffset="63-82" id="DDI-PubMed.31564513.s1.e2" text="Hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.31564513.s1.e0" e2="DDI-PubMed.31564513.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31564513.s1.e0" e2="DDI-PubMed.31564513.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31564513.s1.e0" e2="DDI-PubMed.31564513.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31564513.s1.e1" e2="DDI-PubMed.31564513.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31564513.s1.e1" e2="DDI-PubMed.31564513.s1.e2" /></sentence><sentence text="Hypertension is a major risk factor for cardiovascular diseases, necessitating hypertension control" /><sentence text=" Antihypertensive drugs are more potent when administered in combinations of 2 or 3 different classes of drugs" /><sentence text=" One such therapy includes a combination of an angiotensin receptor blocker, a calcium channel blocker, and a diuretic"><entity charOffset="47-58" id="DDI-PubMed.31564513.s4.e0" text="angiotensin" /><entity charOffset="79-86" id="DDI-PubMed.31564513.s4.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.31564513.s4.e0" e2="DDI-PubMed.31564513.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31564513.s4.e0" e2="DDI-PubMed.31564513.s4.e1" /></sentence><sentence text=" The objective of this study was to evaluate the pharmacokinetic interaction among telmisartan, amlodipine, and hydrochlorothiazide"><entity charOffset="83-94" id="DDI-PubMed.31564513.s5.e0" text="telmisartan" /><entity charOffset="96-106" id="DDI-PubMed.31564513.s5.e1" text="amlodipine" /><entity charOffset="112-131" id="DDI-PubMed.31564513.s5.e2" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.31564513.s5.e0" e2="DDI-PubMed.31564513.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31564513.s5.e0" e2="DDI-PubMed.31564513.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31564513.s5.e0" e2="DDI-PubMed.31564513.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31564513.s5.e1" e2="DDI-PubMed.31564513.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31564513.s5.e1" e2="DDI-PubMed.31564513.s5.e2" /></sentence><sentence text="" /><sentence text="A randomized, open-label, 3-period, 6-sequence, 3-treatment, single-dose crossover study was conducted in healthy male subjects" /><sentence text=" Subjects were randomly assigned to 1 of 6 sequences and one of the following treatments was administered in each period: treatment A, co-administration of one tablet of telmisartan 80 mg and one tablet of amlodipine 10 mg; treatment B, one tablet of hydrochlorothiazide 25 mg alone; and treatment C, co-administration of all 3 investigational products"><entity charOffset="170-181" id="DDI-PubMed.31564513.s8.e0" text="telmisartan" /><entity charOffset="206-216" id="DDI-PubMed.31564513.s8.e1" text="amlodipine" /><entity charOffset="251-270" id="DDI-PubMed.31564513.s8.e2" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.31564513.s8.e0" e2="DDI-PubMed.31564513.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31564513.s8.e0" e2="DDI-PubMed.31564513.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31564513.s8.e0" e2="DDI-PubMed.31564513.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31564513.s8.e1" e2="DDI-PubMed.31564513.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31564513.s8.e1" e2="DDI-PubMed.31564513.s8.e2" /></sentence><sentence text=" Serial blood samples were collected up to 144 hours postdose" /><sentence text=" Plasma drug concentrations were measured by using LC/MS-MS" /><sentence text=" Pharmacokinetic parameters, including Cmax and AUC0-last, were determined by using noncompartmental analysis" /><sentence text=" The geometric least squares mean ratios and associated 90% CIs of log-transformed Cmax and AUC0-last for separate administration or co-administration were calculated to evaluate pharmacokinetic interactions" /><sentence text="" /><sentence text="Twenty-seven subjects completed the study" /><sentence text=" The geometric least squares mean ratios and 90% CIs of Cmax and AUC0-last were 1" /><sentence text="02 (0" /><sentence text="85-1" /><sentence text="21) and 1" /><sentence text="04 (0" /><sentence text="97-1" /><sentence text="13) for telmisartan; 1"><entity charOffset="8-19" id="DDI-PubMed.31564513.s21.e0" text="telmisartan" /></sentence><sentence text="00 (0" /><sentence text="95-1" /><sentence text="04) and 0" /><sentence text="95 (0" /><sentence text="91-0" /><sentence text="99) for amlodipine; and 0"><entity charOffset="8-18" id="DDI-PubMed.31564513.s27.e0" text="amlodipine" /></sentence><sentence text="88 (0" /><sentence text="82-0" /><sentence text="96) and 0" /><sentence text="86 (0" /><sentence text="82-0" /><sentence text="90) for hydrochlorothiazide, respectively"><entity charOffset="8-27" id="DDI-PubMed.31564513.s33.e0" text="hydrochlorothiazide" /></sentence><sentence text=" No serious adverse events were recorded, and all reported adverse events were of mild intensity" /><sentence text="" /><sentence text="The pharmacokinetic parameters of telmisartan, amlodipine, and hydrochlorothiazide when administered separately or co-administered were compared, and all the parameters met the criteria for pharmacokinetic equivalence"><entity charOffset="34-45" id="DDI-PubMed.31564513.s36.e0" text="telmisartan" /><entity charOffset="47-57" id="DDI-PubMed.31564513.s36.e1" text="amlodipine" /><entity charOffset="63-82" id="DDI-PubMed.31564513.s36.e2" text="hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.31564513.s36.e0" e2="DDI-PubMed.31564513.s36.e0" /><pair ddi="false" e1="DDI-PubMed.31564513.s36.e0" e2="DDI-PubMed.31564513.s36.e1" /><pair ddi="false" e1="DDI-PubMed.31564513.s36.e0" e2="DDI-PubMed.31564513.s36.e2" /><pair ddi="false" e1="DDI-PubMed.31564513.s36.e1" e2="DDI-PubMed.31564513.s36.e1" /><pair ddi="false" e1="DDI-PubMed.31564513.s36.e1" e2="DDI-PubMed.31564513.s36.e2" /></sentence><sentence text=" Combination therapy of these 3 drugs had no significant impact on the pharmacokinetic parameters of each drug" /><sentence text=" (ClinicalTrials" /><sentence text="gov Identifier: NCT03889145)" /><sentence text="" /></document>